Hepatitis B: Report of prevalence and access to healthcare among Chinese residents in Sheffield UK

Vedio, Alicia; Ellam, H; Rayner, Frances; Stone, Brian; Kudesia, Goura; McKendrick, Michael W.; Green, Stephen T

doi:10.1016/j.jiph.2013.05.004

Cited by 19 publications

(42 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other studies have shown no difference in treatment uptake rates among immigrants [79]. Lack of insurance coverage [34] and lack of access to specialist physicians [78] were felt to be barriers to treatment in some studies. Therefore, a concerted system-wide approach is required to identify and treat a significant proportion of migrants with viral hepatitis, in order to reduce the burden of chronic liver disease in this population.…”

Section: Improving Case Identification and Treatment Among Migrantsmentioning

confidence: 93%

“…Estimates suggest that 31 US outreach programs active in 2008 screened only 21,000 individuals [74]. Studies on viral hepatitis treatment rates and efficacy among immigrants are limited [76][77][78]. One Italian study showed that immigrants were significantly less likely than Italian-born patients to receive HBV antiviral therapy [76].…”

Section: Improving Case Identification and Treatment Among Migrantsmentioning

confidence: 99%

See 1 more Smart Citation

Immigration and viral hepatitis

Sharma

Carballo

Feld

et al. 2015

Journal of Hepatology

134

103

View full text Add to dashboard Cite

WHO estimates reveal that the global prevalence of viral hepatitis may be as high as 500 million, with an annual mortality rate of up to 1.3 million individuals. The majority of this global burden of disease is borne by nations of the developing world with high rates of vertical and iatrogenic transmission of HBV and HCV, as well as poor access to healthcare. In 2013, 3.2% of the global population (231 million individuals) migrated into a new host nation. Migrants predominantly originate from the developing countries of the south, into the developed economies of North America and Western Europe. This mass migration of individuals from areas of high-prevalence of viral hepatitis poses a unique challenge to the healthcare systems of the host nations. Due to a lack of universal standards for screening, vaccination and treatment of viral hepatitis, the burden of chronic liver disease and hepatocellular carcinoma continues to increase among migrant populations globally. Efforts to increase case identification and treatment among migrants have largely been limited to small outreach programs in urban centers, such that the majority of migrants with viral hepatitis continue to remain unaware of their infection. This review summarizes the data on prevalence of viral hepatitis and burden of chronic liver disease among migrants, current standards for screening and treatment of immigrants and refugees, and efforts to improve the identification and treatment of viral hepatitis among migrants.

show abstract

Section: Improving Case Identification and Treatment Among Migrantsmentioning

confidence: 93%

Section: Improving Case Identification and Treatment Among Migrantsmentioning

confidence: 99%

Immigration and viral hepatitis

Sharma

Carballo

Feld

et al. 2015

Journal of Hepatology

134

103

View full text Add to dashboard Cite

show abstract

“…Among Asian migrants, it was 0.1% for people born in India, 1.5% for people born in Bangladesh, 1.8% for people born in Pakistan [35], 8.7% for Chinese people [36], and 1.7% among women coming from high prevalence countries [33]. No cases were found among 36 newly arrived migrants who were screened in London, but the sample was too small to draw any conclusion [34].…”

Section: Hepatitis B Virusmentioning

confidence: 95%

Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence

Mipatrini¹,

Stefanelli

Severoni

et al. 2017

Pathogens and Global Health

167

122

View full text Add to dashboard Cite

The decline of immunization rates in countries of origin of migrants and refugees, along with risky conditions during the journey to Europe, may threaten migrants' health. We performed a systematic review of the scientific literature in order to assess the frequency of vaccine preventable diseases, and vaccination coverage among migrants and refugees in Europe. To this end, Medline and Cochrane databases were considered. After the screening and the selection process, 58 papers were included in the review. We focused on the following vaccinepreventable diseases: hepatitis B, measles, rubella, mumps, tetanus, poliomyelitis, pertussis, diphtheria, meningitis, and varicella. The results were presented as a qualitative synthesis. In summary, several studies highlighted that migrants and refugees have lower immunization rates compared to European-born individuals. Firstly, this is due to low vaccination coverage in the country of origin. Then, several problems may limit migrants' access to vaccination in Europe: (i) migrants are used to move around the continent, and many vaccines require multiple doses at regular times; (ii) information on the immunization status of migrants is often lacking; (iii) hosting countries face severe economic crises; (iv) migrants often refuse registration with medical authorities for fear of legal consequences and (v) the lack of coordination among public health authorities of neighboring countries may determine either duplications or lack of vaccine administration. Possible strategies to overcome these problems include tailoring immunization services on the specific needs of the target population, developing strong communication campaigns, developing vaccination registers, and promoting collaboration among public health authorities of European Countries. Background and aims

show abstract

“…10 A 2013 UK study demonstrated that 1.1% of tested individuals were positive for HBsAg; 11 in 2009, the prevalence of HBV among migrants in the UK was estimated to be 4%, 12 ranging from 0.1% to 17.4% depending on ethnic group and study method. [13][14][15][16][17][18] In 2012, the National Institute for Health and Care Excellence (NICE) recommended that all people born in a country with HBV prevalence of ≥2% should be offered a HBV test and that testing is offered in primary care. 19 In 2011, approximately 7.5 million (13%) individuals living in England and Wales were born outside of the UK.…”

Section: Introductionmentioning

confidence: 99%

Low hepatitis B testing among migrants: a cross-sectional study in a UK city

et al. 2016

View full text Add to dashboard Cite

BackgroundIn 2012, hepatitis B virus (HBV) testing of people born in a country with a prevalence of ≥2% was recommended in the UK. Implementation of this recommendation requires an understanding of prior HBV testing practice and coverage, for which there are limited data. AimTo estimate the proportion of migrants tested for HBV and explore GP testing practices and barriers to testing. Design and settingA cross-sectional study of (a) migrants for whom testing was recommended under English national guidance, living in Bristol, and registered with a GP in 2006-2013, and (b) GPs practising in Bristol.

show abstract

Hepatitis B: Report of prevalence and access to healthcare among Chinese residents in Sheffield UK

Abstract: This model of outreach testing is helpful for addressing health inequalities afflicting the UK's Chinese community.

Cited by 19 publications

References 16 publications

Immigration and viral hepatitis

Immigration and viral hepatitis

Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence

Low hepatitis B testing among migrants: a cross-sectional study in a UK city

Contact Info

Product

Resources

About